Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration. by Denis Mustafov (19137870)

“…Microscopic images of colonies were taken at ×40 magnification. The data represents mean values and standard deviation, n = 3. <b>Legends:</b> ns: non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.…”

Stability differences between condition 1 and other conditions across participants on the non-hemiparetic side (NHP) side. by Hyung Suk Yang (20442438)

Subjects:

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

“…Microscopic images were captured at ×40 magnification. Data represent mean values ± standard deviation, n = 3. <b>Legends:</b> ns: non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.…”

Elevated concentrations of serum MMA among participants with decreased cognitive performance. by Yige Liu (11940344)

Distribution of patients in the 4 age groups, mean value of IC-volume from both sides and separately for the left and right ICs. by Pingling Kwok (14896191)

Subjects:

Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

The small blue circles show the IC-volume (mean of left and right) from 72 males and the small red squares from 51 females as a function of age. by Pingling Kwok (14896191)

Subjects:

The diagram shows the mean IC-volume of both sides as a function of age with the degree of hearing loss as defined in the methods from class 1 (normal to moderate in both ears) to... by Pingling Kwok (14896191)

Subjects:

Most significant muscle activation values. by María Benito-de-Pedro (22057468)

Subjects:

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

“…In both group, the DPSI also decreased significantly one month post-treatment compared to before and after treatment (P = 0.040 and P = 0.018, respectively). …”

Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Significant repeated measurements sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Significant single measurement sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Average stability values (mean ± standard deviation) and statistical results. by Hyung Suk Yang (20442438)

Subjects:

Mean signal intensities obtained for each analyte at three different tissue-to-solvent volume proportions. by Ewa Paszkowska (21246702)

Subjects:

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye. by Yasuyuki Sotani (20114144)

Subjects: